GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Debt-to-EBITDA

EV Biologics (EV Biologics) Debt-to-EBITDA : -1.12 (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

EV Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $6.47 Mil. EV Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0.00 Mil. EV Biologics's annualized EBITDA for the quarter that ended in Dec. 2017 was $-5.78 Mil. EV Biologics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2017 was -1.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for EV Biologics's Debt-to-EBITDA or its related term are showing as below:

YECO's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.43
* Ranked among companies with meaningful Debt-to-EBITDA only.

EV Biologics Debt-to-EBITDA Historical Data

The historical data trend for EV Biologics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Debt-to-EBITDA Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Debt-to-EBITDA
0.72 0.57 0.87 -0.21 -1.78

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -1.03 -0.05 N/A -1.12

Competitive Comparison of EV Biologics's Debt-to-EBITDA

For the Biotechnology subindustry, EV Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where EV Biologics's Debt-to-EBITDA falls into.



EV Biologics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

EV Biologics's Debt-to-EBITDA for the fiscal year that ended in Jun. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.347 + 0) / -5.817
=-1.78

EV Biologics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.469 + 0) / -5.78
=-1.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2017) EBITDA data.


EV Biologics  (OTCPK:YECO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


EV Biologics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of EV Biologics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics Generates Mesenchymal Stem Cell Lines

By ACCESSWIRE ACCESSWIRE 02-21-2023

EV Biologics NFT Dividend Information

By ACCESSWIRE ACCESSWIRE 08-09-2021

EV Biologics Signs MSA with LONZA Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 05-17-2022

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics Announces NFT Dividend

By ACCESSWIRE ACCESSWIRE 07-14-2021